Controlled Lecithin Release from a Hierarchical Architecture on Blood-Contacting Surface to Reduce Hemolysis of Stored Red Blood Cells
Controlled Lecithin Release from a Hierarchical Architecture on Blood-Contacting Surface to Reduce Hemolysis of Stored Red Blood Cells
复制标题
受控卵磷脂从血液接触表面的分层结构中释放，以减少储存红细胞的溶血
DOI：
10.1021/am502241v
复制
发表时间：
2014-06-25
影响因子：
9.5
通讯作者：
Yin, Jinghua
中科院分区：
文献类型：
--
作者：
Shi, Qiang;Fan, Qunfu;Yin, Jinghua
体内植入装置和非聚氯乙烯容器在体外保存红细胞引起的红细胞溶血近年来受到广泛关注。为了开发具有长期抗溶血能力的血液接触生物材料，我们提出了一种简便的方法，在聚环氧乙烷(PEO)/卵磷脂纳米/微纤维(SEBS)表面构建了一种亲水性的三维分层结构。该方法是将PEO/卵磷脂纤维静电纺丝到聚乙二醇甲基醚甲基丙烯酸酯[P(PEGMEMA)]修饰的SEBS表面，使SEBS适合于体外保存红细胞。我们证明了所构建的三维结构是由亲水的微纤维和纳米纤维组成的，在血液中立即转变为水凝胶网络；卵磷脂的控制释放是通过PEO/卵磷脂水凝胶的逐渐溶解实现的，卵磷脂与红细胞的相互作用保持了膜的弹性和正常的红细胞形状。因此，血液接触表面减少了对红细胞膜的机械和氧化损伤，导致保存的红细胞的低溶血率。本工作不仅为制备高血液相容性的RBC体外储存生物材料开辟了新的途径，也为体内植入抗溶血生物材料的设计和开发提供了基本原则。
Hemolysis of red blood cells (RBCs) caused by implant devices in vivo and nonpolyvinyl chloride containers for RBC preservation in vitro has recently gained much attention. To develop blood-contacting biomaterials with long-term antihemolysis capability, we present a facile method to construct a hydrophilic, 3D hierarchical architecture on the surface of styrene-b-(ethylene-co-butylene)-b-styrene elastomer (SEBS) with poly(ethylene oxide) (PEO)/lecithin nano/microfibers. The strategy is based on electrospinning of PEO/lecithin fibers onto the surface of poly [poly(ethylene glycol) methyl ether methacrylate] [P(PEGMEMA)]-modified SEBS, which renders SEBS suitable for RBC storage in vitro. We demonstrate that the constructed 3D architecture is composed of hydrophilic micro- and nanofibers, which transforms to hydrogel networks immediately in blood; the controlled release of lecithin is achieved by gradual dissolution of PEO/lecithin hydrogels, and the interaction of lecithin with RBCs maintains the membrane flexibility and normal RBC shape. Thus, the blood-contacting surface reduces both mechanical and oxidative damage to RBC membranes, resulting in low hemolysis of preserved RBCs. This work not only paves new way to fabricate high hemocompatible biomaterials for RBC storage in vitro, but provides basic principles to design and develop antihemolysis biomaterials for implantation in vivo.